Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
about
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerSuppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosisIn-depth analysis shows synergy between erlotinib and miR-34aEGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancerClinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanismEGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialLKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.Acquired resistance to drugs targeting receptor tyrosine kinasesTetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.Modeling the Etiology of p53-mutated Cancer Cells.Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAILRe-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.Accomplishments in 2007 in biologic markers for gastrointestinal cancersEGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentEnhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancerThe PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.Fas death pathway in sarcomas correlates with epidermal growth factor transcription.Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling.First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?Acquired Resistance to Drugs Targeting Tyrosine Kinases.[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF.Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways.Modular pore-forming immunotoxins with caged cytotoxicity tailored by directed evolutionThe effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
P2860
Q28396304-90EDFADA-2F2B-413A-B731-4A6FE9E5B413Q28477887-9C30B6D0-130D-4F6F-95B9-FB888F47AF8FQ28539851-EF653E75-F84E-4452-BCA2-B47F80E1C4D1Q33574958-27E58884-F223-4BD0-901C-D8DB208F57F1Q33834851-D236915E-70A0-4494-9DCD-8AB030738B18Q34500155-291326D4-DF05-477D-8CA4-80008130733BQ34633719-C81CFD3B-EF42-4265-9CA2-DB2A0FF329ABQ35678436-5166D7DF-57D2-4435-8D55-61C6B39BC639Q35801173-F431B830-C19E-4FFA-A448-F10356215C99Q35823437-115088BF-7CE0-47B1-8029-F5170948B122Q36280333-C2C271DA-590E-4526-B378-9AE68C16243DQ36876179-D2CF49F4-E2AF-40E7-B03E-65B608777FEDQ36896150-2BC9F79D-FF87-4D48-9148-4570AABF1C0FQ36962950-18E6E5DC-C49E-43F6-846D-9D55C53CF3F1Q37000191-B462F4A8-BE02-4122-8524-D2623632BD0AQ37128041-E67A3435-F20E-4A22-B014-0D38C606092DQ37149168-C07C8749-D1FF-4446-9BB5-40C721B8FC1FQ37174372-DC4EF330-DA31-479A-B440-3424082C153FQ37262314-8CA0EFA3-59ED-4B3C-B029-610A238A1BC5Q38798148-42A6896E-B143-4B4C-89A9-D4C7AC25607BQ39463417-8C6290AB-139A-49FB-BC50-9CB8BF2BFCAEQ39730112-88C65A50-55A9-4788-827A-5F1AB9760BB0Q39989937-EE7A643E-84CE-4D19-A781-83D908C6F1B3Q41329887-B008C55B-D196-4C3E-8CF7-84A0E7F0CDBFQ41831075-373FB69B-4862-4995-8812-FAE607F84F81Q42418384-AD94E8B3-B2AE-4615-81CA-C18C8DD6F29BQ50073382-997B6808-389C-4DF8-BF8B-8BC7CD5743BCQ53701267-14A65092-CFB2-4BE0-A20B-883192BEE3CCQ54536910-C263C751-5B46-4230-AA1A-6001B7C2CA3CQ54590223-F8022D32-B630-4BAE-B929-F86BBDAA54A6Q54786239-9594AC35-106F-48EB-8901-CD678803E6C0Q54978574-E8A3D0D9-8217-4540-8D98-5E1FDEC517D7Q56872060-3EA04767-DF76-4D93-9DEC-73CC429A5EB2Q57816535-806E6590-F8E2-4471-9EBB-6C05C413C5EE
P2860
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chemotherapy-induced epidermal ...... -small cell lung cancer cells.
@en
type
label
Chemotherapy-induced epidermal ...... -small cell lung cancer cells.
@en
prefLabel
Chemotherapy-induced epidermal ...... -small cell lung cancer cells.
@en
P2093
P1476
Chemotherapy-induced epidermal ...... n-small cell lung cancer cells
@en
P2093
Daniel B Longley
Donal M Kelly
Eric Van Cutsem
Joan Kyula
Patrick G Johnston
Sandra Van Schaeybroeck
Susan A Stokesberry
P304
P356
10.1158/1535-7163.MCT-05-0446
P577
2006-05-01T00:00:00Z